

Pediatric Central IRB Meeting Agenda

Friday, January 20, 2017 11:00 am – 11:25 am Eastern Time Agenda

I. General Business

• Next Meetings: Thursday, February 9, 2017 and Friday, February 24, 2017

II. Amendment Review

ADVL1515, A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors (Activation Amendment, Protocol Version Date 12/16/16)